Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021

Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a conference call on March 11, 2021, at 4:30 p.m. EST to discuss its fourth quarter and full-year 2020 financial results as well as updates on its business and pipeline. The call will be accessible via phone or an audio webcast on the company’s website. Spero focuses on developing novel treatments for multi-drug-resistant bacterial infections and rare diseases, with key products including tebipenem HBr, a potential first oral carbapenem antibiotic for complicated urinary tract infections, and SPR720 for rare pulmonary diseases.

Positive

• Scheduled conference call to discuss financial results and business updates, potentially boosting investor confidence.
• Positive top-line results from Phase 3 ADAPT-PO clinical trial of tebipenem HBr for cUTI and AP reported in September 2020.

Negative

• None.

CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on March 11, 2021 at 4:30 p.m. EST to report its fourth quarter and full-year 2020 financial results and provide an update on its business and pipeline.

To access the call, please dial (877) 705-6003 (domestic) or (201) 493-6725 (international) and refer to conference ID 13716494. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Spero Investor and Media Contact:
Sharon Klahre
Vice President, Investor Relations
857-242-1547
IR@sperotherapeutics.com

 

FAQ

When is Spero Therapeutics' financial results conference call?

The conference call is scheduled for March 11, 2021, at 4:30 p.m. EST.

What is the focus of Spero Therapeutics?

Spero Therapeutics focuses on developing treatments for multi-drug-resistant bacterial infections and rare diseases.

What product candidates is Spero Therapeutics developing?

Spero is developing tebipenem HBr for complicated urinary tract infections and SPR720 for rare pulmonary diseases.

What were the results of the tebipenem HBr clinical trial?

The Phase 3 ADAPT-PO clinical trial of tebipenem HBr reported positive top-line results in September 2020.